Observational Ocrelizumab MS Verismo Study

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Multiple Sclerosis
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Signed informed consent
    2. Have a diagnosis of MS
    3. Newly treated with ocrelizumab (within 30 days before baseline visit [study entry]) according to the local label irrespective of the reason for starting ocrelizumab (ocrelizumab cohort)
    4. OR
    5. Newly treated with one of the following 6 approved MS DMTs: alemtuzumab, cladribine, dimethyl fumarate, fingolimod, natalizumab, or teriflunomide according to the local label irrespective of the reason for starting a new MS DMT (internal comparator cohort)

You may not be eligible for this study if the following are true:

    1. Patients who have any prior exposure to rituximab or to any anti CD-20 therapy for MS
    2. Active participation in interventional clinical trials for MS



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.